A5019052809- Bladder and Urothelial Cancer Treatments
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Genetic factors in colorectal cancer
- Chemotherapy-induced organ toxicity mitigation
- Pancreatic and Hepatic Oncology Research
- Esophageal Cancer Research and Treatment
- Multiple and Secondary Primary Cancers
- Cancer Cells and Metastasis
- Exercise and Physiological Responses
- Thermal Regulation in Medicine
- Systemic Lupus Erythematosus Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
National Center for Cancer Care and Research
2024
Riyadh Armed Forces Hospital
2024
King Fahad Specialist Hospital
2021-2024
University of Sheffield
2024
Juravinski Cancer Centre
2018-2020
McMaster University
2018
NewYork–Presbyterian Brooklyn Methodist Hospital
2014
Immune checkpoint inhibitors, including PD-L1 (programmed death ligand-1) inhibitors have well documented anticancer therapeutic effect in most types of cancers but its use the treatment ovarian cancer is not yet proven. The aim our study to explore predictive biomarkers and association with outcomes. We investigated role expressions tumor microenvironment cells immune stem different cancer.A total 119 surgical archived samples were collected from pathology department at King Fahad...
Introduction Bladder cancer is one of the most prevalent cancers worldwide, with significant morbidity and mortality rates. Treatment options for metastatic urothelial carcinoma (mUC) primarily include platinum-based chemotherapy. Cisplatin-based chemotherapy conventionally used treating mUC, but many patients are ineligible due to various factors such as poor performance status, creatinine clearance, neuropathy, cardiac function. Carboplatin-based therapy another alternative, which...
Abstract Background: Hotspot activating mutations in AKT1 and PIK3CA represent a rare but potentially unique subset of metastatic prostate cancers (mPCa). The accompanying genomic clinical features these patients are currently unknown. Preclinical evidence suggests that unconstrained PI3K signaling via PTEN loss may render androgen receptor (AR)-targeted therapy less effective. Given the availability agents target nodes within pathway, elucidating properties AKT1/PIK3CA mutant their response...